| Company | Headquarters | Annual Revenue (USD) | Year |
| Thermo Fisher Scientific | Waltham, Massachusetts, USA | $45.67 billion | 2024 |
| Lonza Group | Basel, Switzerland | $6.79 billion | 2024 |
| Cryoport, Inc. | Knoxville, Tennessee, USA | $370 million | 2024 |
| Marken (part of UPS) | Durham, North Carolina, USA | $500 million | 2024 |
| World Courier | Richmond, Virginia, USA | $1.3 billion | 2024 |
| Patheon (part of Thermo Fisher Scientific) | Durham, North Carolina, USA | $2.8 billion | 2024 |
| Recipharm AB | Stockholm, Sweden | $1.3 billion | 2024 |
| World Courier | Lexington, Massachusetts, USA | $1.3 billion | 2024 |
Headquartered in Waltham, Massachusetts, USA
Established in 2006 after Thermo Electron and Fisher Scientific merged.
A global leader in scientific instrumentation, reagents, and consumables, specializing in lab products, clinical diagnostics, and life sciences.
Mass spectrometry instruments
PCR reagents
Chromatography systems
Diverse product portfolio across scientific sectors
Strong global presence with over 80,000 employees
Leadership in biotechnology and pharmaceuticals
Acquired Life Technologies (2014), expanding its capabilities in life sciences.
Acquired Patheon (2017), further enhancing its manufacturing capabilities in drug development.
Intense competition in life sciences research tools
Challenges in maintaining growth across all product segments
Navigating regulatory complexities in multiple global markets
Launched new genome editing tools in 2025, focusing on CRISPR technology advancements.
Increased investment in digital solutions for laboratories, improving efficiency and data integration.
Headquartered in Basel, Switzerland
Founded in 1897, Lonza is a leading global supplier of life sciences tools and services, particularly focused on biotechnology, pharmaceuticals, and healthcare.
Cell and gene therapies
Biologics manufacturing services
Custom development services
Leading role in cell and gene therapy manufacturing
Strong collaborations with pharmaceutical giants
High-quality biologic and biosimilar products
Acquired Capsugel in 2017, expanding its pharmaceutical services.
Recent investment in gene therapy infrastructure, improving production scalability.
High capital investment required for biotech manufacturing
Regulatory challenges in international markets
Pressure to innovate faster in the cell therapy space
Expanded its cell and gene therapy manufacturing capacity in 2025.
Announced strategic partnership with a global biopharma company to advance mRNA technology.
Headquartered in Knoxville, Tennessee, USA
Founded in 2008, Cryoport specializes in the transportation of temperature-sensitive biological products for the pharmaceutical and biotechnology industries.
Cryogenic shipping solutions
Cold chain logistics
Cryoport Express
Industry leader in cryogenic logistics
Comprehensive, global temperature-controlled shipping network
Trusted by pharmaceutical companies for vaccine and gene therapy logistics
Acquired Cryoport Express (2020), strengthening its shipping network.
Recent acquisition of Nordic Cold Storage, enhancing its European footprint.
High cost of specialized storage and transportation
Navigating the complexities of international shipping regulations
Managing capacity for large-scale shipments
Developed new ultra-low temperature storage solutions in 2025.
Expanded its temperature-controlled shipping solutions to support the COVID-19 vaccine distribution.
Headquartered in Durham, North Carolina, USA
Established in 1980, Marken is a global provider of logistics and supply chain solutions for the pharmaceutical, biotechnology, and life sciences industries.
Clinical trial logistics services
Global temperature-controlled shipping
Cold chain solutions
Expertise in clinical trial management logistics
Strong global presence with over 40 locations worldwide
Integration with UPS for enhanced logistics capabilities
Acquired by UPS in 2016, expanding its capabilities in the pharmaceutical logistics sector.
Recently expanded its offerings in temperature-controlled packaging.
Competition with other pharmaceutical logistics providers
Complexities in meeting regulatory requirements across different countries
Rising demand for faster and more cost-effective logistics solutions
Launched a new real-time monitoring system for cold chain logistics in 2025.
Announced expanded partnerships with leading pharmaceutical companies to improve supply chain efficiency.
Headquartered in Richmond, Virginia, USA
Founded in 1969, World Courier is a global provider of specialty logistics services, particularly focused on temperature-sensitive and life sciences shipments.
Cold chain logistics services
Clinical trial transportation
Custom packaging solutions
Strong expertise in global logistics for life sciences
Robust infrastructure for temperature-sensitive shipments
Part of the AmerisourceBergen Corporation, offering strong industry ties
Acquired by AmerisourceBergen in 2014, significantly expanding its global footprint.
Continual investment in cold chain infrastructure to meet increasing demand.
Managing complex international regulatory compliance
Maintaining operational efficiency as demand for cold chain logistics rises
Competition from other specialty logistics providers
Introduced new cold chain tracking technology in 2025 for enhanced monitoring during transit.
Announced expansion into emerging markets to support global pharmaceutical shipments.
Headquartered in Lexington, Massachusetts, USA
Established in 1990, Xylogics provides specialized cold storage and cryogenic storage solutions for the pharmaceutical and biotechnology industries.
Cryogenic storage systems
Cold storage containers
Biorepository solutions
Expertise in cryogenic preservation
Advanced technology for temperature monitoring
Strong relationships with biotech research institutions
Acquired by BioLife Solutions in 2019, expanding its product range in cryogenic storage.
Integrated new technologies to enhance storage solutions in 2025.
High capital investment required for cold storage systems
Navigating complex regulatory standards across different markets
Expanding product lines to meet increasing demand in gene therapy
Launched a new line of cryogenic storage containers for gene therapy products in 2025.
Expanded production capacity to meet growing demand in Asia.
Headquartered in Durham, North Carolina, USA
Founded in 1974, Patheon is a contract development and manufacturing organization (CDMO) serving the pharmaceutical industry.
Biologics manufacturing services
Drug formulation and packaging
API manufacturing
Strong expertise in drug development and manufacturing
A global network of manufacturing facilities
Acquired by Thermo Fisher in 2017, enhancing its capabilities in pharmaceuticals
Acquired by Thermo Fisher in 2017, significantly expanding its capacity and services.
Recently expanded its biologics manufacturing capabilities to meet rising demand.
Navigating regulatory hurdles in different global markets
Increasing competition from other CDMOs
Maintaining operational efficiency while scaling production
Introduced a new continuous manufacturing platform in 2025.
Announced major investments to expand biologics production in North America.
Headquartered in Stockholm, Sweden
Founded in 1995, Recipharm is a leading CDMO providing services to the pharmaceutical and biotechnology sectors.
Oral solid dosage formulations
Sterile products manufacturing
Biologics development services
Strong focus on the production of both small and large molecules
Global manufacturing presence with over 30 facilities
Extensive experience in biologics and complex drugs
Acquired by the EQT Private Equity Group in 2015, expanding its international footprint.
Recently acquired a facility in Spain to increase its sterile product manufacturing capacity.
Competition from other established CDMOs
Regulatory complexities in biologics manufacturing
Rising cost pressures from raw materials
Expanded its biologics manufacturing capabilities in 2025.
Partnered with a leading pharmaceutical company for the development of a new vaccine.
The global cell and gene supply chain solutions market size is calculated at US$ 3.54 billion in 2024, grew to US$ 4.09 billion in 2025, and is projected to reach around US$ 14.95 billion by 2034. The market is expanding at a CAGR of 15.54% between 2025 and 2034.
Rising CDMOs & CROs: Cell and gene therapies are gaining significant attention due to their potential in curing rare diseases and delivering better outcomes than other therapeutics. Due to the rising demand pharmaceutical and biotech companies face challenges in their supply chain and logistics processes. Due to this, a lot of CDMOs and CROs are entering into the cell and gene supply chain solutions market to provide supply chain solutions to pharma and biotech companies.
For instance,
In January 2025, although cell and gene therapy is developing rapidly, the industry still uses antiquated, laborious methods for sterile processing, such as tube welding or biosafety cabinets, according to Troy Ostreng, Senior Product Manager for CPC's biopharmaceutical division. To create a sterile flow route, customers may now simply snap the connection halves together in CGT processing components that come with the MicroCNX Nano connectors. This is a significant development for applications of CGT.
Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com
